Urovant Reports Publication of New Efficacy, Safety Data On Gemtesa For Overactive Bladder
Urovant Sciences, a wholly-owned subsidiary of Sumitovant Biopharma Ltd, announced the
Earnings Scheduled For January 26, 2022
Companies Reporting Before The Bell
• Blue Foundry (NASDAQ:BLFY) is projected to report earnings for its fourth quarter.
SVB Leerink Maintains Market Perform on Myovant Sciences, Lowers Price Target to $21
SVB Leerink analyst Roanna Ruiz maintains Myovant Sciences (NYSE:MYOV) with a Market Perform and lowers the price target from $23 to $21.
Sumitovant Biopharma Highlights Clinical, Regulatory And Commercial Achievements Across Portfolio Of Companies In Q2 2021
Sumitovant Biopharma, Inc. today announced that its portfolio of four wholly-owned subsidiary companies
Myovant To Participate In Evercore ISI HealthCONx Conference Nov. 30 At 11:45 a.m. EST
Myovant Sciences (NYSE:MYOV), a healthcare company focused on redefining care for women and for men, will participate in the Evercore ISI 4th Annual HealthCONx Conference on November 30, 2021. David Marek, Chief
SVB Leerink Maintains Market Perform on Myovant Sciences, Lowers Price Target to $23
SVB Leerink analyst Roanna Ruiz maintains Myovant Sciences (NYSE:MYOV) with a Market Perform and lowers the price target from $24 to $23.
Why Did Myovant Sciences Shares Fall Despite Q2 Earnings Beat?
Tucked in its Q2 earnings release, Myovant Sciences Ltd (NYSE: MYOV) said that Pfizer Inc (NYSE: PFE) has notified its option decision for international rights to relugolix in oncology.